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Abstract
Myelodysplastic syndromes (MDSs) represent clonal hematopoietic stem cell (HSC)
disorders in which genetic and/or epigenetic alteration are involved in the normal function
of hematopoietic stem and progenitor cells. This results in the development of blood
cytopenias and bone marrow dysplasia. In recent years, therapy with hypomethylating
agents (HMAs) in combination with supportive therapies is recommended as frontline
treatment for patients with high-risk MDSs according to International Prognostic Scoring
System (IPSS HR-MDS). Therapy with HMAs is essential namely for IPSS HR-MDS
patients who do not proceed to immediate allogeneic stem cell transplantation (al‐
loSCT). For IPSS LR-MDS (International Prognostic Scoring System, low-risk MDSs)
patients, however, supportive therapies and growth factors are the mainstay of treatment.
Some patients in this group are treated with immunomodulatory agents derived from
thalidomide (lenalidomide) or using immunosuppressive therapy (IST). The therapeu‐
tic decisions can change during the course of the disease based on changes in risk-
category and the functional status of patients, in response to prior therapies, changes in
patient preferences, and other factors.
Resistance to chemotherapy is a serious obstacle to the successful treatment of overall
malignancies, including AML and MDS. The failure of therapeutic treatment may be due
to the development of multidrug resistance (MDR) phenotype. MDR represents the
induction of large-scale defensive mechanisms from which the upregulation of membrane
transporters (like P-glycoprotein – P-gp) effluxing chemotherapeutic drugs from tumor
cells represents the most observed molecular causality. Other mechanisms of MDR include
drug metabolism, alterations in drug-induced apoptosis, epigenetic changes, epithelial-
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mesenchymal transition, alteration in drug targets structures, and acceleration of DNA
repair.
The present contribution represents a state-of-the-art review of available knowledge
about this issue.
Keywords: myelodysplastic syndromes, acute myeloid leukemia, multidrug resist‐
ance, lenalidomide, 5-azacytidine, 5-aza-2-deoxyazacytidine
1. Introduction
Myelodysplastic syndromes (MDSs) represent the group of disorders associated with altered
hematopoietic stem cells (HSCs) that lead to inefficient hematopoiesis [1]. This clinically results
in dysplasia in one or more myeloid cell lineages, and variable degrees of cytopenias. The mean
age of MDS patients’ diagnosis ranges from 60 to 70 years. The incidence of MDS varied from
4.3 to 1.8 per 100,000 individuals per year in the US and Europe, respectively. Incidence slightly
favors Caucasian males. MDS can lead to acute myeloid leukemia (AML) in 10–15% of patients.
Improvements in cytogenetic analysis techniques enable predicting the risk of MDS patients
lapse into AML and the selection of optimal therapy [2]. The International Prognostic Scoring
System (IPSS) described in the 1990s [3] is still commonly used. This scoring system defines
how to measure the risk of patients’ development from MDS to AML, and recommends
dividing patients into four groups (low, intermediate 1, intermediate 2, and high risk). In lower
risk patients, a combination of supportive care (includes transfusions of blood products,
antibiotics) with substance improving erythropoiesis, immunosuppressive therapy, immuno‐
modulatory therapy, and stem cell transplantation has been used. Treatment options for
patients diagnosed as higher risk include demethylating agents, cytotoxic chemotherapy, bone
marrow HSC transplantation, and experimental treatments in clinical trials [4].
2. Treatment options
The only curative option for patients with MDS represents hematopoietic bone marrow stem
cell transplantations. However, alloSCT is not available for all patients because of the comor‐
bidities of elderly patients [1]. Therefore some patients cannot be treated with alloSCT and
other treatment options have to be used.
2.1. IPSS low-risk MDS patients’ treatment option
Supportive care is an important therapy for the management of patients with low-risk MDS,
as well as patients with poor disease prognosis which due to age or physical condition could
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not be treated with more intensive forms of therapy [5]. Several low-risk patients are dependent
on blood transfusions. However, patients treated with blood transfusions may be overloaded
with iron ions, so that iron chelation therapy is required [6]. Due to the partial dysfunction of
immunity, antibiotics are needed for treatable infections [7].
There are three commonly used therapies for low-risk MDS patients: i. erythropoiesis-
stimulating agents (ESAs); ii. immunosuppressive therapy; and iii. immunomodulatory
therapy with thalidomide derivative lenalidomide (revlimid). The treatment of patients with
ESAs leads to significant erythroid response in 20–70% of unselected patients with MDS [1].
A median response for treatment with erythropoietin and colony-stimulating factor (CSF)
applied together was 2 years and improves life quality [8]. Several immunosuppressants such
as antithymocyte globulin and cyclosporine A were studied in a randomized phase III clinical
trial. This treatment seems to be associated with hematologic responses in a subset of patients,
however, it was not found to reduce the 2-year transformation and overall survival [9].
Over recent years, attention has been paid to immunomodulatory-acting drugs (IMIDs). The
anti-MDS activity of these drugs involves antiproliferative effects, downregulation of crucial
cytokines, and costimulatory effects on T and NK cells [10]. The IMIDs are thalidomide analogs
which have greater immunological and anticancer properties, but lack the toxicity associated
with thalidomide [11]. Lenalidomide (LEN) was proven to be effective in the treatment of
patients with low-risk MDS, particularly in cases with special molecular feature, i.e., deletions
in the long arm of chromosome 5 [12, 13].
2.2. IPSS high-risk MDS patients’ treatment option
Patients with high-risk MDS have poor outcomes, high probability of AML development, and
without intensive treatment or alloSCT their median survival is limited to 1 year [3]. The
treatment of high-risk MDS patients is based on three commonly used therapies: i. alloSCT; ii.
intensive chemotherapy; and iii. drugs with epigenetic mechanism of action such as deme‐
thylation agents and histone deacetylase inhibitors (HDACi) [1]. Similarly as in low-risk
patients, the application of alloSCT is limited by the patients’ age and overall condition.
About 50% of patients with high-risk MDS achieve complete remission with standard anti‐
leukemic chemotherapy with fludarabine, idarubicin, or topotecan. This therapy could be
improved by a combination of these drugs with intermediate- or high-dose cytosine arabino‐
side [14]. The combination of such therapy with granulocyte colony-stimulating factor (G-CSF)
is well tolerated and highly effective in the remission of both high-risk MDS patients and AML
patients [15].
Inhibitors of histone deacetylase block the deacetylation of histones molecules, i.e., they protect
histones in acetylation forms. The acetylation of histones occurs in the replication- and
transcription-active euchromatin. HDACi could protect euchromatin against formation
changes to heterochromatin that is replication and transcription inactive. The effect of HDACi
could be pleiotropic, leading to the induction of differentiation, growth arrest, and finally to
the apoptosis of tumor cells. The mechanisms of HDACi’s effectiveness are under intensive
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debate, and it may be p53 dependent or independent [16]. Valproic acid, entinostat, vorinostat,
and other HDCAi are under intensive research with the aim of characterizing their effective‐
ness against MDS [16].
The cytosine analogs 4-amino-1-(β-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one – azacytidine
(AzaC) and 4-amino-1-(β-D-deoxyribofuranosyl)-1,3,5-triazin-2(1H)-one – deoxyazacytidine
(decitabine, DAC), which were described as cancerostatic agents in the late 1960s and the early
1970s [17, 18], were found to effectively block DNA methylation [19]. Their effectiveness in
inducing beneficial effects in the treatment of MDS [20] and AML [21] was already proven.
The downregulation of DNA methylation induced by AzaC and DAC is related to the ability
of this substance to be artificially incorporated into DNA instead of cytosine, which has to be
methylated by DNA methyltransferase [22]. This could be considered as a major principle of
DAC action. In contrast to DAC’s effects, AzaC is more complex and also involves incorpora‐
tion into mRNA, tRNA, and rRNA, which disrupts nucleic acid and protein metabolism
leading to apoptosis in addition to the incorporation of substances into DNA [22, 23]. Consis‐
tently AzaC induced more pronounced cell damage effects than DAC [24].
3. Drug resistance of MDS and AML patients
3.1. Mechanisms of drug resistance of neoplastic cells
The multidrug resistance (MDR) of neoplastic cells represents a real obstacle in the effective
treatment of neoplastic diseases [25]. MDR could be an inherent property of tissue from which
neoplastic cells were developed – primary (intrinsic) MDR, or could be induced by prior
treatment with anticancer drugs – secondary (acquired) MDR (reviewed in [26]). In both cases
the neoplastic cells exert reduced sensitivity to more than one drug that differs in structure
and pharmacological efficiency. In many cases, cells with resistance to a large scale of diverse
drugs are present in cancer tissue. Several mechanisms are involved in the mediation of MDR,
which can be divided into seven groups (Figure 1, reviewed in [27]):
i. Potentiating drug metabolism via the induction/activation of phase I and phase II
detoxification enzymes
ii. Potentiating cell drug efflux via the induction/activation of membrane drug trans‐
porter predominantly members of the ABC family
iii. Alteration in drug target structures
iv. Acceleration of DNA-repair
v. Changes in epigenetic regulation
vi. Programmed cell death inhibition
vii. Epithelial-mesenchymal transition
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Figure 1. Mechanisms of multidrug resistance.
These mechanisms could act independently or cooperate in the development of MDR in
relation to cancer cells’ specific character. The expression of drug transporters represents the
most observed molecular causality of MDR (reviewed in [28, 29]). At least three transporters
are involved in the reduction of drug sensitivity of neoplastic cells. The best known is P-
glycoprotein (P-gp) that represents an ABCB1 member of the ABC transporter family and was
discovered as the first ABC transporter in 1976 [30]. P-gp could efflux a large scale of different
uncharged substances from cells. Drugs such as colchicine, tacrolimus, and quinidine;
chemotherapeutic agents such as etoposide, doxorubicin, and vinblastine; different lipids and
steroids; xenobiotics; DNA-intercalators such as ethidium bromide; linear or circular peptides
like valinomycin and gramicidin; bilirubin; cardiac glycosides like digoxin; different immu‐
nosuppressive agents; glucocorticoids like dexamethasone; HIV-type 1 antiretroviral therapy
agents like protease inhibitors and nonnucleoside reverse transcriptase inhibitors; and many
others are known to be P-gp substrates. When P-gp is expressed in neoplastic tissue it can
depress cell sensitivity to its substrates several hundred times [31]. Besides this generally
accepted role as a drug transporter, this protein may also play another role as an antiapoptotic
regulatory protein and this role is independent of P-gp efflux activity [29, 32]. This additional
role also enables P-gp to reduce cell sensitivity to substances that are not its substrates, such
as cisplatin several times [33, 34].
Other important transporters involved in MDR are ABCC1-3 members of the ABC transport‐
ers’ family, also known as multidrug-resistant associate proteins 1–3 (MRP1-MRP3) that in
contrast to P-gp are specific to negatively charged organic anions (reviewed in [35]). They are
also specific for drug conjugates with glucuronic acid and glutathione as a product of phase
II enzyme drug detoxification.
One more transporter ABCG2 member of the ABC transporter family is often described to be
involved in MDR [36]. This transporter also known as breast cancer-resistant protein (BCRP)
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may efflux substances such as mitoxantrone, methotrexate, topotecan, imatinib, and others.
The substrate specificity of P-gp, MRP1-3, and BCRP overlaps, and each could be responsible
for the efflux of common substrate.
The drug could be detoxified by phase I and phase II detoxification enzymes that secure
oxidative and conjugative ways of drug modification which are mediated by cytochrome P450
(CYP) monooxygenases and conjugating enzymes (glutathione S-transferases [GSTs] and
UDP-glucuronyl-transferase), respectively [37]. The CYP family, particularly the CYP3A
members of the CYP family, may be involved in the reduction of cell sensitivity to several
drugs. The transcriptional control of the CYP family is mediated by pregnane X nuclear
receptor, i.e., the same nuclear receptor involved in P-gp expression [38].
GSTs represent a group of enzymes that are often involved in the protection of cells against
toxic stress [39]. These enzymes catalyze the conjugation of several xenobiotics with reduced
glutathione [40]. The actions of GSTs are often coordinated with MRPs that transport several
conjugates of drugs and reduced glutathione [41]. While P-gp cannot transport glutathione
conjugates, coordinated coexpression of P-gp and GST was observed in vitro using AML cell
lines [42].
Alteration in drug target structures such as the mechanism of MDR represents a large group
of diverse changes in regulatory pathways, which is finally responsible for the downregulation
or upregulation of drug molecular target. An example of this behavior alteration of topoiso‐
merase II, such as the molecular causality of neoplastic cell resistance to topoisomerase
poisons, could be performed (reviewed in [28]).
The repair of DNA primarily damaged by drugs’ direct action, or secondarily by the elevation
of oxygen reactive species formation, clearly yields to the drug resistance of neoplastic cells
[27]. The therapeutic effects of DNA-damaging drugs in cancer treatment are given by the
equilibrium between drug-induced DNA damage and the effectiveness of DNA repair
mechanisms. The inhibition of repair pathways used in conjunction with DNA damaging
chemotherapy could sensitize cancer cells and therefore increase the efficacy of therapy [27].
Epithelial-mesenchymal transition is a mechanism predominantly taking part in solid tumor
metastatic processes. This mechanism could play only a minor role (if any) in drug resistance
development in MDS and AML patients.
The high expression levels of antiapoptotic proto-oncogene of the Bcl-2 family (such as BCL-2,
Bcl-XL, Mcl-1, Bcl-w, and Bfl-1) were often reported to be associated with in vitro resistance
to chemotherapeutic agents, poor clinical outcomes in cases of AML [43], and in cases of adults
with acute lymphoblastic leukemia [44]. Bcl-2 was shown to be restricted in tissues character‐
ized by apoptotic cell death [45]. Antiapoptotic proteins of the Bcl-2 family hetero-oligomerize
in vivo with a conserved homolog – proapoptotic member of the Bcl-2 family (such as Bax),
and this process is known to modulate apoptosis [46]. The translocation of the Bax (or other
proapoptotic protein) monomer from the cytosol to the mitochondria followed by the forma‐
tion of BAX homo-oligomers represents a physiological death stimulus, which may be
prevented by the presence of the Bcl-2 protein (or other antiapoptotic proteins) [47]. Therefore
for apoptosis progression, an equilibrium between anti- and proapoptotic proteins plays a
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crucial role. This is molecularly regulated by the p53 known as the central regulator of
apoptosis [48]. This is consistent with known data about the role of the mutated form of TP53
in cancer [49, 50].
Epigenetic regulations are involved in the development of MDR directly by the downregula‐
tion or upregulation of important genes responsible for cell death or survival. For example,
tumor-suppressor genes are often silenced via hypermethylation, and oncogenes are overex‐
pressed via hypomethylation [27]. Epigenetics could also play an indirect role in cell drug
sensitivity by the following mechanism: the opening of the chromatin structure, which is
prerequisite for DNA replication and transcription, and to produce uncovered DNA that is
more accessible for drug-induced DNA damage. This is consistent with more pronounced
DNA damage induced with drugs in more proliferating and/or transcriptionally active cells.
Hypermethylation of the MDR1 promoter was associated with transcriptional repression and
chromatin structural changes [51]. The demethylation of this promoter in cancer cell lines was
found to elevate the multidrug-resistant phenotype [52].
Epigenetic mechanisms can also influence DNA damage repair. For example, DNA mismatch
repair processes can be lost due to the hypermethylation of the human mutL homolog 1
(hMLH1) gene promoter, which can lead to cancer development [27].
Demethylation by DAC may have a role in increasing the efficacy of chemotherapy for patients
with tumors, as characterized by high hMLH1 promoter methylation and low hMLH1
expression [53].
3.2. Resistance to immunomodulatory drugs
Over recent years, attention has been paid to exploiting the immunomodulatory effects
primarily obtained for thalidomide [54], which has resulted in novel IMIDs. The anti-MDS
activity of these drugs (namely LEN) was proven for low-risk MDS, particularly with 5q
deletion (del[5q]) [55]. This action is attributed to several mechanisms that involve antiproli‐
ferative effects, downregulation of crucial cytokines, and costimulatory effects on T and NK
cells [10]. However, the exact mechanism of IMIDs’ action in MDS treatment is still not fully
understood. The IMIDs’ immunomodulatory compounds derived from the thalidomide
structure have greater immunological and anticancer properties, but lack the toxicity associ‐
ated with thalidomide [11]. LEN (Revlimid) was approved for use in low- and intermediate-1-
risk MDS patients who have the deletion 5q chromosome and no other chromosomal
abnormalities, are dependent on red blood cell transfusions, and for whom other treatment
options have been found to be insufficient or inadequate by EMA (European Medicines
Agency) and the FDA (Food and Drug Administration). After LEN treatment, blood transfu‐
sion-independent rates were 56–67%, and median response duration was longer than 104
weeks [1]. Additionally, a significant proportion of these responders achieved cytogenetic
responses (50–76%), indicating a direct cytotoxic effect of LEN on the neoplastic clones,
although a significant proportion of patients develop resistance to this treatment. The study
of cytogenetics and molecular predictors of responses in patients with myeloid malignancies
without del[5q] treated with LEN indicated that treatment could be effective in patients with
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normal karyotype and a gain of 8 chromosome is present [55]. The LEN response was achieved
by one quarter of MDS patients lacking the 5q abnormality. Ebert et al. [56] found that
mononuclear cells from bone marrow aspirates of patients who respond to LEN have a
decreased expression of genes, which are specific to terminal erythroid differentiation,
regardless of the presence or absence of a 5q deletion. Moreover, LEN acts directly on hema‐
topoietic progenitor cells to increase erythropoiesis relative to other lineages.
The mechanism of LEN’s therapeutic effects and the mechanisms that depress its effectiveness
in MDS treatment are not fully understood, but could be related to TP53 mutation (reviewed
in [57]).
TP53-mutated populations seem to be associated with the early stage of low-risk MDS in
patients with del[5q] [58]. However, these authors stated that TP53 mutations could not be
predicted by general clinical features but were associated with p53 overexpression. Specific
R72P polymorphism of TP53 results in two molecular forms of p53. Molecular variant p53-R72
with better mitochondrial localization activates apoptosis more efficiently (by direct induction
of cytochrome c release) than p53-P72 variant [59]. McGraw et al. [60] underscore the distri‐
bution of R72P in MDS and highlight differences between del(5q) and non-del(5q) subtypes
by gene polymorphism and the relationship to LEN response. However, to prove the potential
interaction of R72P variants with germline variants in other key regulators or effectors of the
p53 pathway that may modify MDS risk and LEN treatment response, further research will be
necessary.
Allelic deletion of the RPS14 gene is a key effector of the hypoplastic anemia in patients with
MDS and chromosome 5q deletion [61]. Disruption of ribosome integrity liberates free
ribosomal proteins to bind to and trigger the degradation of E3 ubiquitin-protein ligase MDM2
(a negative regulator of p53), with consequent p53 transactivation. Consistently, p53 is
overexpressed in erythroid precursors of primary bone marrow del(5q) MDS specimens
accompanied by reduced cellular MDM2. LEN may act in the stabilization of MDM2 that leads
to p53 degradation [61].
When LEN was used in establishing human AML cell lines SKM-1 and MOLM-13 for resist‐
ance, only SKM-1 but not MOLM-13 cells developed MDR phenotype with massive expression
of P-gp [62]. Both these cell lines were derived from AML patients, whose disease developed
from MDS. In contrast to MOLM-13 with wild type of p53 [63, 64], SKM-1 represents cells
expressing a mutated p53 form [65]. Thus cells with mutated TP53 could express P-gp under
long-term LEN treatment, which leads to typical P-gp mediated MDR.
3.3. Resistance to hypomethylating agents
In pathogenesis of MDS, both genetics and epigenetics alterations are cooperated. Disruption
of genetic pathways regulating the processes of self-renewal, differentiation, quiescence, and
stem cell-niche signaling contributes to AML transformation. The hypermethylation of
different genes was discussed to be partially responsible for the poor prognosis of MDS
patients [66]. Demethylating agents, such as AzaC and DAC, were shown to induce clinical
responses in 40–70% of MDS patients [67, 68]. Although hypomethylation is considered the
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dominant mode of therapeutic action of these drugs, it may also induce DNA damage and
consequent apoptosis [69]. Interestingly, clinically significant responses to decitabine without
significant toxicity can be seen in patients after nonsuccessful azacitidine therapy [70].
Changes in the expression profile of genes like CD9, GPNMB, FUCA1, ANGPT1, PLA2G7,
TPM1, and ARHGEF3 were observed when CD34+ cells isolated from the bone marrow of
high-risk MDS patients treated in vitro with DAC were compared with CD34+ cells isolated
from patients with untreated early stage Hodgkin's lymphoma taken as a control [66].
AzaC resistance represents a real obstacle for the effective treatment of MDS patients, which
focused the attention of scientists on alternative therapeutic strategies for nonresponsive
patients. For this reason, AzaC-resistant MDS/AML cell lines are established. AzaC-resistant
SKM-1 cells exhibited increased expression of the BCL2L10 member of the antiapoptotic Bcl-2
family that altered apoptosis progression [71]. Interestingly we described the downregulation
and changed molecular form of the Bcl-2 protein identified by polyclonal antibody (sc-492,
Santa Cruz Biotechnology, USA) in our variant of SKM-1 AzaC-resistant cells [42]. Moreover,
other AzaC-resistant AML cells derived from the MOLM-13 cell line exerted similar changes
in the Bcl-2 protein. Significant correlation of AzaC resistance with a percentage of MDS or
AML cells expressing BCL2L10 was established on a group of 77 patients [71].
AzaC resistance could include impaired mitochondrial membrane permeabilization and
caspase activation when AzaC resistant and sensitive SKM-1 myeloid were compared [72]. In
our experiments, when the same cell model was used resistance to AzaC was associated with
strong over expression of P-gp that secured additional resistance to P-gp substrates [42]. This
is a rather interesting finding because AzaC is not a P-gp substrate, and P-gp was not respon‐
sible for AzaC resistance. We obtained similar results using MOLM-13 cells. The activity of
GST was found to be elevated 8 times when AzaC resistant and sensitive SKM-1 and MOLM-13
cells were compared [42].
AzaC induced the upregulation of LC3-II and elevation of cathepsin B activity (both autophagy
markers). Increased basal autophagy was observed in SKM-1 AzaC-resistant cells, but these
cells were resistant to AzaC-mediated autophagy [72]. Autophagy depression using a LC3
silencer revealed the protective function of autophagy in AzaC-sensitive and AzaC-resistant
cells in basal condition [72]. Taking all the facts about apoptosis and autophagy progression
in AML cell models together, it could be concluded that resistance to AzaC is associated with
alterations of both processes via impaired homeostasis of its key regulators such as Bcl-2 family
proteins and LC3. However, the exact mechanism of this feature is not fully understood and
future research will be necessary.
Enzymes involved in cytidine metabolism such as cytidine deaminase (CDA) and deoxycyti‐
dine kinase (DCK) seem to be responsible for the primary (intrinsic) AzaC resistance, because
nonresponders of AzaC have a 3-fold higher CDA/CDK ratio. There were no significant
differences at relapse in DAC metabolism genes, and no CDK mutations were detected [73].
MDSs are characterized by mutations in genes encoding epigenetic modifiers and aberrant
DNA methylation. Clonal mutation of TP53 and non-receptor type 11 protein tyrosine
phosphatase were associated with shorter overall survival, but not the drug response of
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patients. Clonal tet methylcytosine dioxygenase 2 (TET2) mutations predicted a response when
subclones were treated as wild type. The highest response rate was observed in patients with
a mutation in the TET2 gene without a clonal mutation of the trancriptional regulator encoded
by ASXL1 gene. [74].
While somatic mutations did not differentiate responders from nonresponders for DAC
treatment, differentially methylated regions of DNA at baseline distinguished responders
from nonresponders. In responders, the upregulated genes included those that are associated
with the cell cycle, potentially contributing to effective DAC incorporation [75].
While DAC is generally accepted as a hypomethylating agent, it may exert a therapeutic effect
also in another way. The acceleration of reactive oxygen species induced with DAC could take
place in the overall DAC effect. However, reactive oxygen species accumulation was not
always present in the sample of AML patients after DAC treatment. Therefore, the relevance
of reactive oxygen species generation in the mechanism of DAC pharmacological effectiveness
should be studied more intensively in the future [76].
3.4. Resistance to intensive chemotherapy
MDS intermediate- or high-risk patients may be treated with an intensive chemotherapy
regimen that is similar as used for AML treatment. A combination of drugs such as cytosine
arabinoside, fludarabine, idarubicin, and topotecan, etc. could be used [14]. This chemotherapy
is oriented on destroying abnormal blood cells or preventing their growth. For patients who
are eligible, bone marrow transplantation is recommended after this therapy.
The development of MDR resistance during the application of this protocol is similar as for
other types of neoplastic diseases, and may involve each of the mechanisms described in
Chapter 3. The combination of drug-resistant mechanisms that are included in MDR pheno‐
type development during high intensive treatment depends on the specific patient molecular
feature, previous therapeutic history, and drugs applied during previous treatment.
3.5. Resistance to CD33-targeted therapy
Progressive methods of MDS treatment represent antibody targeting therapy with cytotoxic
agents linked to humanized antibodies against antigens specific to neoplastic cells. Both MDS
and AML are characterized by the presence of undifferentiated CD33-positive myeloblast in
peripheral blood and bone marrow, compared with healthy control [77]. CD33 is a 67 kDa
glycoprotein present on the surface of myeloid cells, and is a member of the sialic acid binding
immunoglobulin-like lectin family of proteins [78]. After binding to an appropriate antibody,
CD33 is rapidly internalized into leukemia cells [79, 80]. This action enables the use of a
humanized CD33 antibody, conjugated to cytotoxic agents for targeted immunotherapy [78,
79]. Gemtuzumab ozogamicin represents antibody drug (from a class of calicheamicins)
conjugates [7, 78–81]. This therapy has proven to be effective, but resistance to treatment could
be developed. Another immune-targeting preparation is AVE9633 (immunoconjugate of
humanized monoclonal CD33 antibody, linked through a disulfide bond to the maytansine
derivative DM4) that was used in the treatment of several leukemia cell lines [82]. The activity
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of P-gp was attributed as a critical factor in depressing the success of this therapy. P-gp
mediated the efflux of drug liberated from linkage with antibody due to intracellular enzymes
was attributed as being responsible for this resistance [82]. However, a significant inverse
correlation was determined for the expression of P-gp and CD33 in the AML blast obtained
from patients [81]. We described the strong downregulation of CD33 on mRNA and the protein
level in P-gp positive SKM-1 cells selected for resistance by LEN, vincristine, mitoxantrone, or
in P-gp positive MOLM-13 cells selected for resistance by vincristine or mitoxantrone [62].
Upregulation of CD33 expression level was also observed in P-gp silenced cell lines. Therefore,
the failure of CD33-targeted therapy of patients with AML blast overexpressing P-gp could be
caused by a lack of CD33 as an antibody target structure on the cell surface.
3.6. Detection of drug-resistant markers in neoplastic cells
Cellular expression of drug-resistant markers could be monitored on mRNA level (RT-PCR
methods) or protein level (Western blot and immunofluorescence flow cytometry) [83].
Proteins active in MDR development like ABC transporters, drug metabolizing enzymes,
antiapoptotic proteins, and many others could be detected by these methods. Transport
activity of drug transporters could be measured using depressed intracellular retention of their
fluorescent substrates by flow cytometry. Retentions of calcein/AM, rhodamine 123, or
doxorubicin were often used for P-gp efflux activity detection directly in cells isolated from
patients [84]. Activities of detoxification enzymes could be monitored by appropriate sub‐
strates, which enzymatic modifications induce changes in either fluorescence or light absorb‐
ance properties. Conjugation of 1-chloro-2,4-dinitrobenzene with reduced glutathione as a
result of GST activity could be taken as example [42]. Specific mutations of genes active in
MDR development (like TP53) could be detected using mutation analysis including specifically
designed PCR reaction, denaturing high-performance liquid chromatography, or DNA-
sequencing techniques. Alteration in drug-induced apoptosis could be monitored as difference
in drug-induced DNA-fragmentation by electrophoresis or using comet assay [85]. Applica‐
tion of oligonucleotide microarray for human genome represents available methods to obtain
complex information about expression profiles of MDR-associated genes in patients [86].
Moreover, when nonresponders and responders will be compared using oligonucleotide
microarrays, new information about involving different genes’ expression in MDR develop‐
ment could be obtained. Cytotoxic effects of several drugs could be monitored directly in cells
isolated from patient samples using assays based on reduction of formazan (like MTT assay)
by intracellular dehydrogenases, or liberation of fluorescent label from its esters (like fluores‐
cein diacetate) by intracellular esterases.
4. Perspectives
MDSs represent a very diverse group of hematological malignancies. Treatment of this disease
involves several drugs such as LEN, AzaC, and DAC. Unfortunately, the exact mechanism of
action is still not fully understood. Therefore, prediction of the response to this treatment is
still very complicated. For this reason, a detailed knowledge of the molecular causality of MDS
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and AML progression will be necessary. Moreover, unclear questions about the molecular
mechanisms of these drugs should be answered. Resistance to treatment use for AML and
MDS still represents serious problems with causality not fully understood. Research oriented
on these topics will bring new knowledge and new predictive molecular markers that will
enable the better selection of effective therapy for each patient.
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